| Reference | Product Name | Utilisation | Conditionnement |
|---|---|---|---|
| CTI 002-100 | i-Tracker Infliximab | Quantitative determination of Infliximab (anti-TNFα) in human serum and plasma samples | 100 tests |
| CTI 003-100 | i-Tracker Anti-Infliximab | Quantitative determination of anti-Infliximab antibodies in human serum and plasma samples | 100 tests |
| CTA 002-100 | i-Tracker Adalimumab | Quantitative determination of Adalimumab (anti-TNFα) in human serum et plasma samples | 100 tests |
| CTA 003-100 | i-Tracker Anti-Adalimumab | Quantitative determination of anti-Adalimumab antibodies in human serum and plasma samples | 100 tests |
| CTG 002-50 | i-Tracker Golimumab (in dev.) | Quantitative measurement of Golimumab (anti-TNFα) in serum and plasma samples | 50 tests |
| CTG 003-50 | i-Tracker Anti-Golimumab (in dev.) | Quantitative measurement of anti-Golimumab antibodies in serum and plasma samples | 50 tests |
| CTU 002-50 | i-Tracker Ustekinumab (in dev.) | Quantitative measurement of Ustekinumab in human serum and plasma samples | 50 tests |
| CTU 003-50 | i-Tracker Anti-Ustekinumab (in dev.) | Quantitative measurement of anti-Ustekinumab antibodies in human serum and plasma samples | 50 tests |
| CTV 002-50 | i-Tracker Vedolizumab (in dev.) | Quantitative measurement of Vedolizumab in human serum and plasma samples | 50 tests |
| CTV 003-50 | i-Tracker Anti-Vedolizumab (in dev.) | Quantitative measurement of anti-Vedolizumab antibodies in human serum and plasma samples | 50 tests |